Biodel, a specialty pharmaceutical company focused on the development and commercialization of treatments for endocrine disorders such as diabetes and osteoporosis, announced the terms of its IPO Thursday. The company plans to offer 5 million shares at a price between $14.00 and $16.00 per share. Morgan Stanley and Banc of America are the lead managers on the deal.
